Skip to main content
SpringerLink
Log in

Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2

  • Published:
In Vitro Cellular & Developmental Biology - Animal Aims and scope Submit manuscript

Abstract

Ceramidases are key enzymes that decrease ceramide levels in cells. A reduction in ceramide concentration impairs ceramide signalling, and results in apoptosis resistance in cancer cells. This study investigates the potential for ceranib-2, a novel ceramidase inhibitor, to affect the survival and/or promote apoptosis of prostate cancer cells (LNCaP and DU145) in vitro. Cell viability was determined using MTT, and apoptosis assessed via flow cytometry. We examined structural changes with both confocal and transmission electron microscopes. Ceranib-2 concentrations of 0.1, 1, 5, 10, 25 and 50 μM were applied to LNCaP and DU145 cell lines. The corresponding reduction in LNCaP cell viability (against the control) was 84%, 80%, 64%, 56%, 40% and 15% after 24 h, and 81%, 74%, 60%, 55%, 27% and 11% after 48 h. For DU145 cells, viability was reduced to 84%, 82%, 63%, 50%, 41% and 18% after 24 h, and 64%, 42%, 30%, 20%, 8% and 5% after 48 h. Following treatment with 25 and 50 μM ceranib-2, the respective observed rates of early apoptosis in LNCaP cells were 23% and 36% after 24 h and 27% and 58% after 48 h. The morphological and ultrastructural signs of apoptosis detected were fragmented nuclei, chromatin condensations and cytoskeleton laceration. The inhibitory effects of ceranib-2 on prostate cancer cell survival are dose and time dependent. For LNCaP cells, ceranib-2 toxicity was predominately apoptotic in nature, while for DU145 cells, cell death may be related to non-apoptotic mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.

Similar content being viewed by others

References

  • Beckham TH, Elojeimy S, Cheng JC, Turner LS, Hoffman SR, Norris JS, Liu X (2010) Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets 14:529–39

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Draper JM, Xia Z, Smith RA, Zhuang Y, Wang W, Smith CD (2011) Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther 10:2052–61

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Engedal N, Saatcioglu F (2001) Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 46:289–297

    Article  CAS  PubMed  Google Scholar 

  • Gewies A, Rokhlin OW, Cohen MB (2000) Ceramide induces cell death in the human prostatic carcinoma cell lines PC3 and DU145 but does not seem to be involved in Fas-mediated apoptosis. Lab Invest 80:671–676

    Article  CAS  PubMed  Google Scholar 

  • Holman DH, Turner LS, El-Zawahry A, Elojeimy S, Liu X, Bielawski J, Szulc ZM, Norris K, Zeidan YH, Hannun YA, Bielwska A, Norris JS (2008) Lysosomotric acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Paharmacol 61:231–242

    Article  CAS  Google Scholar 

  • Huerta S, Gaulet EJ, Huerta-Yepez S, Livingston EH (2007) Screening and detection of apoptosis. J Surg Res 139:143–56

    Article  CAS  PubMed  Google Scholar 

  • Kim YJ, Kim EA, Sohn UY, Yim CB, Im C (2010) Cytotoxic activity and structure activity relationship of ceramide analogues in Caki-2 and HL-60 cells. Korean J Physiol Pharmacol 14:441–447

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, Keane TE, Hannun YA, Norris JS (2009) Acid ceramidase up-regulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 13:1449–58

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP (2003) Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implications of epidermal growth factor receptor down regulation and ceramide production. Prostate 56:1–12

    Article  CAS  PubMed  Google Scholar 

  • Mossmann T (1983) Rapid colorimetric assay of cellular growth and survival: application to proliferation and cytotoxicity assay. J Immun Method 65:55–63

    Article  Google Scholar 

  • Norris JS, Bielawska A, Day T, El-Zawahry A, Elojeimy S, Hannun YA, Holman D, Hyer M, Landon C, Lowe S, Dong JY, Mckillop J, Norris K, Obeid L, Rubinchik S, Tavassoli M, Tomlinson S, Voelkel JS, Liu X (2006) Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 13:1045–51

    Article  CAS  PubMed  Google Scholar 

  • Ogretmen B, Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604–16

    Article  CAS  PubMed  Google Scholar 

  • Oskouian B, Saba J (2010) Cancer treatment strategies targeting sphingolipid metabolism. Adj Exp Med Biol 688:185–205

    Article  CAS  Google Scholar 

  • Proksch D, Klein JK, Arenz C (2011) Potent inhibition of acid ceramidase by novel B-13 analogues. J Lipids 20011:1–8

    Article  Google Scholar 

  • Ravindran J, Prasad S, Aggarwal BB (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11:595–610

    Article  Google Scholar 

  • Realini N, Solorzano C, Pagliuca C, Pizzirani D, Armirotti A, Luciani R, Costi MP, Bandiera T, Piomelli D (2013) Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Sci Rep 8:3. doi:10.1038/srep01035

    Google Scholar 

  • Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, Turner LS, Cheng J, Bielawska A, Bielawski J, Keane TE, Obeid LM, Hannun YA, Norris JS, Liu X (2007) The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 6:1455–60

    Article  CAS  PubMed  Google Scholar 

  • Samsel L, Zaidel G, Drumgoole HM, Jelovac D, Drachenberg C, Rhee JG, Brodie AMH, Bielawska A, Smyth MJ (2004) The ceramide analog B13 induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58:382–393

    Article  CAS  PubMed  Google Scholar 

  • Samuel RD, John TI (2002) A history of prostate cancer treatment. Nat Rev Cancer 2:389–96

    Article  Google Scholar 

  • Seelan RS, Qian C, Yokomiza A, Bostwick DG, Smith DI, Liu W (2000) Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 29:137–46

    Article  CAS  PubMed  Google Scholar 

  • Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, Clavie PA (2001) Induction of apoptotic cell death and prevention of tumor growth by ceramidase analogues in metastatic human colon cancer. Cancer Res 61:1233–40

    CAS  PubMed  Google Scholar 

  • Stiban J, Fistere D, Colombini M (2006) Dihydroceramide hinders ceramide channel formation: implications on apoptosis. Apoptosis 11:773–780

    Article  CAS  PubMed  Google Scholar 

  • Strelow A, Bernardo K, Klages SA, Linke T, Sandhoff K, Kronke M (2000) Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 192:601–11

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Vejselova D, Kutlu HM, Kuş G, Kabadere S, Uyar R (2014) Cytotoxic and apoptotic effects of ceranib-2 offering potential for a new antineoplastic agent in the treatment of cancer cells. Turk J Biol 38:916–921

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a grant (project number: 1401S007) from Anadolu University Scientific Research Projects Committee.

Author information

Authors and Affiliations

  1. Department of Health Programme, Open Faculty, Anadolu University, 26480, Eskisehir, Turkey

    Gokhan Kus

  2. Department of Physiology, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey

    Selda Kabadere & Ruhi Uyar

  3. Department of Biology, Faculty of Science, Anadolu University, Eskisehir, Turkey

    Hatice Mehtap Kutlu

Authors
  1. Gokhan Kus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Selda Kabadere
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruhi Uyar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hatice Mehtap Kutlu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gokhan Kus.

Additional information

Editor: Tetsuji Okamoto

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kus, G., Kabadere, S., Uyar, R. et al. Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2. In Vitro Cell.Dev.Biol.-Animal 51, 1056–1063 (2015). https://doi.org/10.1007/s11626-015-9932-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11626-015-9932-9

Keywords

Search

Navigation